A randomized double-blind controlled trial of the use of dydrogesterone in women with threatened miscarriage in the first trimester: study protocol for a randomized controlled trial

Diana Man Ka Chan, Ka Wang Cheung, Sofie Shuk Fei Yung, Vivian Chi Yan Lee, Raymond Hang Wun Li, Ernest Hung Yu Ng, Diana Man Ka Chan, Ka Wang Cheung, Sofie Shuk Fei Yung, Vivian Chi Yan Lee, Raymond Hang Wun Li, Ernest Hung Yu Ng

Abstract

Background: Miscarriage is a common complication of pregnancy occurring in 15-20 % of all clinically recognized pregnancies. Currently, there is still no good scientific evidence to support the routine use of progestogens for the treatment of threatened miscarriage because the existing studies were not large enough to show a significant difference and some of them were not randomized or double-blind.

Methods: This is a double-blind, randomized controlled trial. A total of 400 patients presenting with first-trimester threatened miscarriage will be enrolled. They will be randomized to take dydrogesterone 40 mg per os, followed by 10 mg per os three times a day or placebo until twelve completed weeks of gestation or 1 week after the bleeding has stopped, whichever is longer. The primary outcome is the percentage of miscarriage before 20 weeks of gestation.

Discussion: We postulate that the dydrogesterone therapy will significantly reduce the risk of miscarriage in women with threatened miscarriage.

Trial registration: This study is registered at ClinicalTrials.gov, NCT02128685 . Registered on 29 April 2014.

Keywords: Dydrogesterone; Progestogen; Randomized controlled trial; Threatened miscarriage.

References

    1. National Institute for Health and Care Excellence. Ectopic pregnancy and miscarriage: diagnosis and initial management. 2012. . Accessed 28 Dec 2015.
    1. Suzumori N, Sugiura-Ogasawara M. Genetic factors as a cause of miscarriage. Curr Med Chem. 2010;17:3431–7. doi: 10.2174/092986710793176302.
    1. Osmana ao lu MA, Erdo an I, Emina ao lu S, Karahan SC, Ozgün S, Can G. The diagnostic value of beta-human chorionic gonadotropin, progesterone, CA125 in the prediction of abortions. J Obstet Gynaecol. 2010;30:288–93. doi: 10.3109/01443611003605286.
    1. Aleman A, Althabe F, Belizan J, Bergel E. Bed rest during pregnancy for preventing miscarriage. Cochrane Database Syst Rev. 2005;2:CD003576.
    1. Harrison RF. A comparative study of human chorionic gonadotropin, placebo, and bed rest for women with early threatened abortion. Int J Fertil Menopausal Stud. 1993;38(3):160–5.
    1. Qureshi NS, Edi-Osagie EC, Ogbo V, Ray S, Hopkins RE. First trimester threatened miscarriage treatment with human chorionic gonadotrophins: a randomised controlled trial. BJOG. 2005;112(11):1536–41. doi: 10.1111/j.1471-0528.2005.00750.x.
    1. Lede R, Duley L. Uterine muscle relaxant drugs for threatened miscarriage. Cochrane Database Syst Rev. 2005;3:CD002857.
    1. Goldstein P, Berrier J, Rosen S, Sacks HS, Chalmers TC. A meta-analysis of randomized control trials of progestational agents in pregnancy. Br J Obstet Gynaecol. 1989;96(3):265–74. doi: 10.1111/j.1471-0528.1989.tb02385.x.
    1. Omar MH, Mashita MK, Lim PS, Jamil MA. Dydrogesterone in threatened abortion: pregnancy outcome. J Steroid Biochem Mol Biol. 2005;97(5):421–5. doi: 10.1016/j.jsbmb.2005.08.013.
    1. Pandian RU. Dydrogesterone in threatened miscarriage: a Malaysian experience. Maturitas. 2009;65(Suppl 1):S47–50. doi: 10.1016/j.maturitas.2009.11.016.
    1. El-Zibdeh MY, Yousef LT. Dydrogesterone support in threatened miscarriage. Maturitas. 2009;65(Suppl 1):S43–6. doi: 10.1016/j.maturitas.2009.11.013.
    1. Druckmann R, Druckmann MA. Progesterone and the immunology of pregnancy. J Steroid Biochem Mol Biol. 2005;97(5):389–96. doi: 10.1016/j.jsbmb.2005.08.010.
    1. Sladek SM, Magness RR, Conrad KP. Nitric oxide and pregnancy. Am J Physiol. 1997;272(2 Pt 2):R441–63.
    1. Hill NC, Selinger M, Ferguson J, Lopez Bernal A, Mackenzie IZ. The physiological and clinical effects of progesterone inhibition with mifepristone (RU 486) in the second trimester. Br J Obstet Gynaecol. 1990;97(6):487–92. doi: 10.1111/j.1471-0528.1990.tb02517.x.
    1. Wahabi HA, Abed Althagafi NF, Elawad M, Al Zeidan RA. Progestogen for treating threatened miscarriage. Cochrane Database Syst Rev. 2011;3:CD005943.
    1. Raghupathy R, Al Mutawa E, Makhseed M, Azizieh F, Szekeres-Bartho J. Modulation of cytokine production by dydrogesterone in lymphocytes from women with recurrent miscarriage. BJOG. 2005;112(8):1096–101. doi: 10.1111/j.1471-0528.2005.00633.x.
    1. Raghupathy R, Al Mutawa E, Makhseed M, Al-Azemi M, Azizieh F. Redirection of cytokine production by lymphocytes from women with pre-term delivery by dydrogesterone. Am J Reprod Immunol. 2007;58(1):31–8. doi: 10.1111/j.1600-0897.2007.00488.x.
    1. Orsal AS, Blois S, Labuz D, Peters EM, Schaefer M, Arck PC. The progesterone derivative dydrogesterone down-regulates neurokinin 1 receptor expression on lymphocytes, induces a Th2 skew and exerts hypoalgesic effects in mice. J Mol Med (Berl) 2006;84(2):159–67. doi: 10.1007/s00109-005-0005-5.
    1. Blois SM, Joachim R, Kandil J, Margni R, Tometten M, Klapp BF, et al. Depletion of CD8+ cells abolishes the pregnancy protective effect of progesterone substitution with dydrogesterone in mice by altering the Th1/Th2 cytokine profile. J Immunol. 2004;172(10):5893–9. doi: 10.4049/jimmunol.172.10.5893.
    1. Joachim R, Zenclussen AC, Polgar B, Douglas AJ, Fest S, Knackstedt M, et al. The progesterone derivative dydrogesterone abrogates murine stress-triggered abortion by inducing a Th2 biased local immune response. Steroids. 2003;68(10-13):931–40. doi: 10.1016/j.steroids.2003.08.010.
    1. Goujard J, Rumeau-Rouquette C. First-trimester exposure to progestagen/oestrogen and congenital malformations. Lancet. 1977;1(8009):482–3. doi: 10.1016/S0140-6736(77)91966-3.
    1. Nora JJ, Nora AH, Blu J, Ingram J, Fountain A, Peterson M, et al. Exogenous progestogen and estrogen implicated in birth defects. JAMA. 1978;240(9):837–43. doi: 10.1001/jama.1978.03290090031012.
    1. Resseguie LJ, Hick JF, Bruen JA, Noller KL, O’Fallon WM, Kurland LT. Congenital malformations among offspring exposed in utero to progestins, Olmsted County, Minnesota, 1936–1974. Fertil Steril. 1985;43(4):514–9. doi: 10.1016/S0015-0282(16)48490-6.
    1. Katz Z, Lancet M, Skornik J, Chemke J, Mogilner BM, Klinberg M. Teratogenicity of progestogens given during the first trimester of pregnancy. Obstet Gynecol. 1985;65(6):775–80.
    1. Raman-Wilms L, Tseng AL, Wighardt S, Einarson TR, Koren G. Fetal genital effects of first-trimester sex hormone exposure: a meta-analysis. Obstet Gynecol. 1995;85(1):141–9. doi: 10.1016/0029-7844(94)00341-A.
    1. Queisser-Luft A. Dydrogesterone use during pregnancy: overview of birth defects reported since 1977. Early Hum Dev. 2009;85(6):375–7. doi: 10.1016/j.earlhumdev.2008.12.016.
    1. Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren